Vertex Gears Up For Next Generation In CF Therapy
This article was originally published in The Pink Sheet Daily
Orkambi posts sales of $131m in its first quarter on the market, reaching 35% of CF patients eligible for therapy under its label. Firm also updated investors on plans for next-generation CF drugs
You may also be interested in...
Although a study testing a combo of the company's cystic fibrosis drug Kalydeco and the investigational VX-661 in patients with minimal CFTR function was ended due to futility, Vertex is on pace for a 2017 filing of the combo in three other CF subpopulations.
South Korea’s healthcare services face both longer-term systemic challenges and short-term disruption from ongoing doctor walkouts over government plans to boost medical trainees. Meanwhile, the local pharma industry is calling for new measures to support the supply of essential drugs.
Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.